- Home
- EXP vs JAZZ Comparison
EXP vs JAZZ Comparison
Compare EXP & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXP | JAZZ |
|---|---|---|
| Founded | 1963 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 10.8B |
| IPO Year | 1994 | 2007 |
Fundamental Metrics
Financial Performance| Metric | EXP | JAZZ |
|---|---|---|
| Price | $226.46 | $167.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | ★ $252.22 | $199.20 |
| AVG Volume (30 Days) | 366.2K | ★ 1.6M |
| Earning Date | 01-28-2026 | 11-05-2025 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 13.52 | N/A |
| Revenue | $2,301,796,000.00 | ★ $4,157,832,999.00 |
| Revenue This Year | $2.81 | $6.00 |
| Revenue Next Year | $3.96 | $6.84 |
| P/E Ratio | $16.65 | ★ N/A |
| Revenue Growth | 1.50 | ★ 4.14 |
| 52 Week Low | $191.91 | $95.49 |
| 52 Week High | $283.00 | $182.99 |
Technical Indicators
Market Signals| Indicator | EXP | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 61.38 | 57.75 |
| Support Level | $216.14 | $161.00 |
| Resistance Level | $229.48 | $168.69 |
| Average True Range (ATR) | 4.98 | 4.96 |
| MACD | 1.55 | -1.99 |
| Stochastic Oscillator | 89.60 | 30.32 |
Price Performance
Historical ComparisonAbout EXP Eagle Materials Inc
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.